Ravelcare (544629)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 89.71% indicates strong capital efficiency when the business is generating profits
• P/E of 21.59 is not excessive if earnings normalize and the zero quarter is an anomaly
• Personal care products can enjoy repeat consumer demand and relatively low cyclicality
• Small market cap of ₹113 Cr leaves room for a niche player to grow if execution improves

Concerns

• Latest quarter sales and net profit of ₹0 Cr are serious red flags, suggesting business disruption or data issues
• Sales growth and profit growth are both 0.00%, showing no momentum
• Piotroski F-Score of 3/9 points to weak operating and financial health
• Missing book value, ROE, debt/equity, and promoter holding data prevent any reliable margin-of-safety calculation; zero dividend yield offers no income support

AI Analysis

Ravelcare is a small personal-care business with a market cap of ₹113 Cr and a share price of ₹164.30. At first glance, a P/E of 21.59 and an ROCE of 89.71% look interesting. That ROCE figure, if genuine, suggests a capital-light business that can earn high returns when it is operating properly. But Benjamin Graham taught me to look behind the numbers. Sales growth is 0.00%, profit growth is 0.00%, and the latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr. That is a massive red flag. A company cannot be valued on a trailing P/E when the engine has suddenly stalled. The Piotroski F-Score of 3/9 also tells me the financial health is weak. I do not have book value, return on equity, debt-to-equity, or promoter holding data. Without those, I cannot calculate a margin of safety. In the personal care industry, a durable moat comes from brand power, distribution reach, and pricing power. Nothing in the data proves Ravelcare has that. The price may look reasonable, but a zero recent quarter makes it a speculation on a rebound, not an investment. As Graham said, price is what you pay, value is what you get. I cannot see the value clearly enough. This could be a turnaround situation, but only if management proves it can generate sales and profits again. Until then, I would rather wait on the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer